| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Galectin Therapeutics Inc (GALT) has 14 insiders with recent SEC Form 4 filings, including 4 buys and 6 sells. GALT is classified in the Biotechnology industry within the Health Care sector.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| 10% | 10.33M | $21.70M | - | |
| 10% | 5.61M | $11.79M | - | |
| CFO | 100.0K | $210.0K | - | |
| CEO | 100.0K | $210.0K | - | |
| Other | 100.0K | $210.0K | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Mar 1, 2021 | 10x Fund, L.P.85 | 10% Owner | Sell | 10,000 | $2.31 | $23,100.00 | -0.2% | |
| Feb 2, 2021 | 10x Fund, L.P.85 | - | Sell | 10,000 | $2.04 | $20,400.00 | -0.2% | |
| Jan 11, 2021 | Amelio Gilbert F | Director | Sell | 60,000 | $2.17 | $130,200.00 | -49.7% | |
| Jan 4, 2021 | 10x Fund, L.P.85 | 10% Owner | Sell | 10,000 | $2.23 | $22,300.00 | -0.2% | |
| Oct 13, 2020 | 10x Fund, L.P.85 | 10% Owner | Sell | 10,000 | $2.97 | $29,700.00 | -0.2% | |
| Sep 4, 2020 | Uihlein Richard E | Director, 10% Owner | Buy | 10,000 | $2.55 | $25,500.00 | +0.1% | |
| Sep 4, 2020 | Freeman Kevin D56 | Director | Buy | 5,000 | $2.57 | $12,848.00 | +25.0% | |
| Mar 19, 2020 | Freeman Kevin D56 | Director | Buy | 6,000 | $1.64 | $9,844.20 | +42.9% | |
| Jan 17, 2020 | 10x Fund, L.P.85 | 10% Owner | Sell | 10,000 | $2.97 | $29,700.00 | -0.2% | |
| Nov 15, 2019 | Freeman Kevin D56 | Director | Buy | 3,000 | $3.36 | $10,075.80 | +27.3% |